Diurnal Group PLC Posting of Annual Report and AGM Notice (3181D)
October 08 2018 - 10:00AM
UK Regulatory
TIDMDNL
RNS Number : 3181D
Diurnal Group PLC
08 October 2018
8 October 2018
Diurnal Group plc
("Diurnal" or the "Company")
Posting of Annual Report and AGM Notice
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces that its Annual Report and Accounts for the
year ending 30 June 2018, together with the notice of Annual
General Meeting (AGM), have today been posted to shareholders.
The documents are being made available at the investor relations
section of the Company's website, www.diurnal.co.uk.
The Company's AGM will be held at 11.00am at the offices of FTI
Consulting LLP, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD
on Wednesday 14 November 2018.
For further information, please visit www.diurnal.co.uk or contact:
Diurnal Group plc +44 (0)20 3727 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
Cantor Fitzgerald Europe (Joint Broker) +44 (0)20 7894 7000
Corporate Finance: Phil Davies, Will Goode,
Michael Boot
Healthcare Equity Sales: Andrew Keith
FTI Consulting +44 (0)20 3727 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBXBDGBDGBGII
(END) Dow Jones Newswires
October 08, 2018 11:00 ET (15:00 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024